Apexium Financial LP Boosts Stock Position in Eli Lilly and Company $LLY

Key Points

• Apexium Financial LP increased its stake in Eli Lilly and Company by 103.9%, acquiring a total of 1,876 shares worth approximately $1.55 million by the end of the first quarter.
• Various other hedge funds also boosted their holdings in Eli Lilly, with 82.53% of the stock currently owned by institutional investors and hedge funds.
• Eli Lilly reported a significant earnings beat with $6.31 earnings per share in its latest quarter, surpassing estimates, and projected a fiscal year 2025 guidance of $21.750-23.000 EPS.

Apexium Financial LP boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 103.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,876 shares of the company's stock after buying an additional 956 shares during the period. Apexium Financial LP's holdings in Eli Lilly and Company were worth $1,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. WestEnd Advisors LLC raised its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its holdings in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter worth $40,000. Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. Finally, O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald cut their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $710.7290 on Friday. The company has a market cap of $672.67 billion, a PE ratio of 46.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.44. The stock's 50 day simple moving average is $754.70 and its 200-day simple moving average is $790.53. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $972.48. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.